11 Most Profitable NASDAQ Stocks to Buy Now
Earlier on May 30, Siebert Financial CIO Mark Malek appeared on CNBC to discuss the tariff headwinds swirling around the markets and which sectors could then rise above the noise...
Posts Tagged ‘NASDAQ:GILD’
11 Best Drug Stocks to Buy According to Hedge Funds
Health and Human Services Secretary Robert F. Kennedy Jr.
Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline
On June 4, Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at $130.
Positive Outlook Boosted Gilead Sciences (GILD) in Q1
Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 investor letter.
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential
On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while maintaining a price target of $135.
Citi Analysts Affirm Buy Rating on Gilead Sciences (GILD) Stock
On June 2, Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.
Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35%
A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc.
Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
10 Unstoppable Dividend Stocks to Buy Now
Dividend-paying stocks are drawing increased attention from investors amid this year’s market volatility.
Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies
Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the "Quant King" of hedge funds due to the extraordinary success of Renaissance...
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Call Transcript April 24, 2025Gilead Sciences, Inc. beats earnings expectations.
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds
On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech sector could be heading into a period of...
11 Most Undervalued Quality Stocks to Buy Now
On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined 'The Exchange' on CNBC to discuss her thoughts on how good quality companies can ride out turbulence...
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter.
7 Most Undervalued Biotech Stocks To Invest In
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector...
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds
The NASDAQ Index closed more than 10% below its December high of 20,174 on March 6, 2025.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Top 10 Stocks Wall Street is Discussing
Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that started during the peak of the pandemic driven by fiscal...
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
10 Stocks That Analysts Think Will Go Up
The S&P 500 index touched an all-time high this week as Mark Zuckerberg’s company's 20-day streak finally came to an end, adding $320 billion to the company’s market cap.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (GILD) on Substack by Disruptive analytics. In this article, we will summarize the bulls’ thesis on GILD.
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Call Transcript February 11, 2025Gilead Sciences, Inc. beats earnings expectations.
Why Gilead (GILD) Is Advancing Today
Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above...
10 Best Wide Moat Stocks to Invest In
Russell Investments continues to monitor and analyze the potential for policy changes in President Trump's second term in office.
10 AI News and Ratings You Should Not Miss
DeepSeek is making significant strides in the artificial intelligence landscape.
8 Best Humane Stocks to Invest in Now
In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies.
Billionaire Steve Cohen’s Top 15 Stock Picks
Steve Cohen is one of the most prominent and successful hedge fund managers in the world, known for his extraordinary trading acumen and ability to generate consistent returns...
15 Best NASDAQ Dividend Stocks To Buy
The NASDAQ, heavily comprised of technology stocks, has been on a consistent upward trajectory for some years.
Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy of the letter can be downloaded here.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD.
Top 20 Dividend Stocks of 2024
Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% in the past week.
13 Best Pharma Dividend Stocks To Buy In 2024
The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, reflecting a shift toward smaller, more strategic transactions...
Jim Cramer Talked About These 8 Stocks
Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of experience.
Gilead Sciences (GILD) Made Big Announcements in Q3
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here.
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024Gilead Sciences, Inc. beats earnings expectations.
10 Best Pharma Stocks To Buy Right Now
Healthcare takes the concept of 'defensive' further than almost any industry, encompassing many companies that provide patient care, engage in the research and development of ...
Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE
As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.
Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks
As the fourth quarter of 2024 starts, the market is once again back to debating about the Federal Reserve's interest rate cuts.
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Call Transcript August 8, 2024Gilead Sciences, Inc. beats earnings expectations.
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter.
Hedge Funds are Bullish on This Gene Therapy Stock
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and ...
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc.
5 Best Depressed Stocks To Buy in 2024
This article presents an overview of 5 Best Depressed Stocks To Buy in 2024. For a detailed overview of such stocks read our article, 12 Best Depressed Stocks To Buy in 2024...
5 Best High-Dividend Stocks to Buy Right Now
In this article, we discuss 5 best high-dividend stocks to buy right now.
